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TOPIC: 
PREVALENCE OF HIV OCULAR MANIFESTATION IN RELATION TO CD4 
COUNT AT ART CENTRE, SMCH, CHENNAI.. 
 
KEYWORD: ocular HIV , HAART. 
 
INTRODUCTION: 
HIV;bane of new era has been a serious health issue since its discovery in the early 
70’s. Although with the current  fall in the incidence globally and India; as per UN 
2012 reports ;India is still the third largest nation with HIV population. 
HIV manifests indirectly and it does so by decreasing the immunity especially CD4 
cells,thereby leading to secondary infections. It affects all systems alike ;eye and its 
adnexa is no exception. 
HIV ocular complications include minor opportunistic infection,tumor, inflammation, 
vasculopathy and retinopathy. It is important that these manifestations are detected 
irrespective of symptoms or history and treated at the earliest possible. 
This study is done  in order to find the prevalence of the various ocular manifestation 
of HIV ,its correlation to CD4 count and the role of HAART.  
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM 
 To evaluate the prevalence of ocular manifestations in HIV seropositive 
patients, attending the ART centre, Stanley Medical College and Hospital. 
 To evaluate how the manifestations correlate to the CD4 count. 
 To evaluate the impact of HAART on ocular HIV manifestations. 
 
METHODS AND MATERIAL 
STUDY DESIGN:  
Cross sectional study was undertaken on 100 HIV seropositive patient attending the 
ART centre with known CD4 count was included in the study.The study period was 
from February 2013 till completion of hundred patients.  
 
INCLUSION CRITERIA 
 HIV seropositve consented patients attending ART centre irrespective of ocular 
complaints, irrespective of treatment status. 
 Any age group  
 CD4 count obtained at the time of examination. 
 
EXCLUSION CRITERIA 
 Severely ill patients. 
 CD4 count could not be obtained. 
 Pre-existing systemic illnesses. 
 
 
The importance of ocular examination in them was thoroughly explained in 
patients own language.Consent in patients own language was obtained from all 
those who were willing to take part in study.Any photographic records of the 
lesions were taken only if the patient consented for the same.Upon completion of 
data collection, statistical analysis was applied. 
 
STATISTICAL ANALYSIS: 
Chi square test was done for statistical analysis of the obtained data. 
 
ROUTINE OCULAR EXAMINATION WAS DONE AS FOLLOWS: 
 Ocular history. 
 Ocular examination included: 
 Best corrected visual acuity. ( Snellen’s chart ) 
 Slit lamp evaluation – Adnexa and Anterior segment  
 Dilated fundus evaluation (0.8 % tropicamide with 5% phenylephirine) – 90 D       
 and 20 D 
 Neuro ophthalmological examination 
 Orbit  
 Tonometry for IOP evaluation 
 Schirmer’s for dry eye evaluation 
 
 Patient with suspected lesions were referred for complete systemic and 
laboratory work up. 
 Serological investigations included TORCH titre, PCR assay for HZV, VZ. 
 Other investigations were done as per clinical indication included CT brain/ 
MRI brain. 
 
 
  
OBSERVATION AND DISCUSSION: 
The mean age of patients in our study was 38.14 +/- 11.84 which fell in line with 
mean age of the comparative studies.Majority of the patient prevalence in our study 
fell under the reproductive age group of 20-40 years. This pattern was similarly 
noticed in Biswas et al , Gururaj et al and Lamichhane G et al study. However our 
prevalence rate of 58 % was closely comparable to the Gururaj et al study which had 
54 %.Also comparable with the Gururaj et al study was the decrease in prevalence 
with increase in age.Of special mention is the similarity in the prevalence of patients 
in the age group < 20 years. 
Our study shows a higher male prevalence in comparison to females. The age gender 
distribution in our study was not significant, p= 0.3. This was also the finding in 
Lamichhane G et all study. 
Sexual route was the most common mode of disease transmission, and this was 
observed in study by Biswas et al and Gururaj et al. Gururaj et al had 1 homosexual 
route of exposure.P value of 0.1274 signifies that the route of exposure has no impact 
the prevalence of the ocular manifestations.Majority of the patients in our study were 
observed in clinical stage I and II. The findings were similar in the Gururaj et al and 
Amare et al study. 
It was observed in our study that all patients those who fell under the Clinical category 
III /IV had ocular HIV manifestation, and mostly of the opportunistic type. This was 
equally observed in the studies to which we compared to in the above table.With p 
value of 0.003 we can conclude that prevalence of ocular manifestation increases with 
the clinical staging of disease. And this is probably due to the increase in the 
opportunistic infection in these stages. This was observed both in  Gururaj et al and 
the Amare et al study as well.We observed an increased prevalence of ocular 
manifestations in the CD4 range of 200 – 500 cells/mm3. This was comparable to the 
Ethiopian study by Amare et al.P value in our study was 0.0235, which was 
significant. This significance was observed in all the above mentioned studies.Hence 
ocular manifestations is seen to increase significantly with decrease in CD4 count, 
especially in levels < 200 cells/mm3.  
Blepharitis and conjunctival microvasculopathy was the commonest anterior segment 
findings observed in this study. The prevalence of both of which were significantly 
higher in comparison to the studies mentioned above.Kaposi sarcoma and conjunctival 
squamous cell carcinoma were nil, and were comparable to the two Indian studies 
mentioned above. These findings were present in the African studies. And this has 
been implicated due to the homosexual practises.we see differences in most of the 
anterior segment presentations in comparison to other Indian studies. This can be 
attributed to the geographical change in location of the study.The prevalence of HIV 
retinopathy, toxoplasmosis acute retinal necrosis and uveitis in our study was 
comparable to the prevalence in Biswas et al study.The same finding was not so with 
CMV retinitis. This limitation was observed probably due to the sample size in our 
study. Ocular TB and syphilis were not recorded in our study. 
 
 
 
 
CONCLUSION 
HIV infection is a problematic communicable disease present in our population, 
affecting commonly the reproductive age group.  HIV manifests in the eye  either 
directly in the form of viral load or causes low immunity thereby increasing 
chances for opportunistic infections.With the introduction of HAART, the life 
expectancy of the patients have significantly increased. However the ocular 
manifestations continue to present in innumerable forms.Not all patients with early 
HIV opportunistic infection present to us with ocular symptoms until unless the 
manifestation is severely blinding and irreversible.Most of the symptomatic 
patients are the ones with blepharitis and conjunctivitis, a non-blinding yet 
troublesome form of disease manifestations.The ART centres in India at present 
practice just the referral of patients for ophthalmological examination only when 
the patient develops ocular complaints.With the number of ocular findings 
observed, our study highlights the need for a routine ophthalmological screening of 
all HIV seropositive patients.We recommend a routine screening of HIV 
seropositive patients upon diagnosis, prior to starting ART therapy to obtain a 
baseline ocular status. Once the patient is started on HAART , he/she  must  
undergo at-least a half yearly ocular examination. This is important for two 
reasons; one to look out for immune reconstitution syndromes, two to identify the 
ocular side effects of HAART.CD4 counts have to be strictly considered while 
monitoring these patients. It serves both as a risk factor as well as an indicator of 
opportunistic manifestations.A very important observation we made was the 
patients non-consenting to any detailed examination outside of the ART centre. 
This was due to the stigma attached to the disease and the fear of being publically 
recognised as HIV seropositive.All this indicates a need for provision of 
ophthalmic setup in the ART centre.This can be made possible with adequate 
resources and trained ophthalmic personnel.  
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PART I 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
HIV-AIDS was discovered in the early 1970’s. Amongst the various 
communicable diseases that have been well controlled with the advancing 
sciences, HIV- AIDS
1
 has been a major challenge. It poses a challenge not just to 
the doctors treating the disease but also to the patient subjected to societal 
stigma. AIDS with its multisystem manifestations calls for an increasing 
attention in understanding the disease and managing it and the associated 
opportunistic infections.  
 
Eye with its adnexa is no exception to HIV infection. Ophthalmic
2
 presentations 
of HIV include microvasculopathy, neuro-ophthalmic disorders, neoplasms and 
opportunistic infections. Mainly seen and examined by the treating physician it 
becomes a necessity that all HIV infected patients undergo routine ophthalmic 
evaluations irrespective of symptoms for early identification of manifestations 
and prompt initiation of treatment to prevent visual loss. 
 
This study was done to find the prevalence of the various ocular manifestation of 
HIV, its correlation to CD4 count and the role of HAART. 
  
REVIEW OF LITERATURE 
1. Ocular manifestation of HIV/AIDS and correlation with CD4+ cells count 
among adult HIV/AIDS patients in Jimma town, Ethiopia: a cross 
sectional study; Sisay Bekele, Yeshigeta Gelaw and Fasil Tessema. 
Prevalence of HIV ocular manifestation was found to be lower than 
previous studies. They concluded this as probable result antiretroviral 
therapy. Low CD4 count is both risk factor and predictor for eye 
involvement in HIV. 
 
2. Clinical study of ocular manifestations in HIV/AIDS and its correlation 
with CD4+T cells; Shivayogi Kusagur, Gururaj .K.J. 
CD4+ cell counts and WHO clinical stage of HIV disease were concluded 
as important predictors of occurrence of ocular morbidity in HIV positive 
individuals. 
 
3. Prevalence of HIV-associated ophthalmic disease among patients 
enrolling for antiretroviral treatment in India: A cross-sectional study ; 
Sophia Pathai, Alaka Deshpande, Clare Gilbert and Stephen D Lawn 
One fifth Pre ART HIV individuals had ocular manifestations requiring 
treatment, and CMVR was the most common presentation. This highlights 
the need for screening HIV positive patients irrespective of ocular 
symptoms. 
 
 4. Pattern of Ocular Manifestation of HIV/ AIDS among Patients on 
HAART in ART Clinic of Gondar University Hospital, Northwest 
Ethiopia; Bemnet Amare, Fisseha Admassu, Yared Assefa, Beyene 
Moges, Jemal Ali and Afework Kassu. 
The study demonstrates the need of eye care package in management of 
HIV/AIDS patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HISTORY 
Theories of HIV origin and its epidemic have baffled many of us for ages. 
Simian immunodeficiency virus from monkeys
3
 spread
4
 into human community 
in various forms thereby mutating to Human immunodeficiency Virus (HIV). 
Homosexual
5
 practice along with social changes and urbanisation
6
 led into its 
amplification in human community.  
 
The virus was identified and named
7
 lymphadenopathy associated virus in 1983 
and renamed as Human lymphotrophic virus-III
8
 in 1984. In the year 1986 both 
names were discarded and the name Human immunodeficiency virus was put 
into use. On retrospective analyses of all the preserved samples (blood, lymph 
node) of suspected deaths (clusters of immunosuppressive episodes) the first 
known case was a documented HIV1 infection from a man in Congo in the year 
1959. Second documentation was from a woman in Congo in 1960. Since then 
number of patients positive for HIV have increased progressively without any 
permanent cure and increasing opportunist infections. 
 
India is home to third largest population
9,10
 of people living with acquired 
immunodeficiency syndrome. The first reported case of HIV in India was by a 
female sex worker from Chennai in 1986. The first ocular lesion in HIV was 
reported from Sankara Nethralaya , Chennai in 1995
11
. 
 
 
GLOBAL SCENARIO 
As on 2012, the estimated number of people living with HIV globally, is 35.3 
(32.2–38.8) million. The number of new infection in 2001 was 3.4 million in 
comparison to 2.3 (1.9–2.7) million new HIV infections in 2012, showing a 33% 
decline in the number of new infections globally
12
. The AIDS related deaths have 
drastically declined from 2.3 million in 2005 to 1.6 million in 2012, a direct 
result of increasing care and antiretroviral treatment. Even India is still the third 
largest nation with HIV population. 
 
In India the new infection number fell from 2.74 lakhs cases in 2000 to 1.16 
lakhs in 2011(57%). An impact of the various interventions under National AIDS 
Control Programme. Of the four high prevalence States in India includes Andhra 
Pradesh, Karnataka, Maharashtra and Tamil Nadu and they account for 53% of 
all HIV infected population in the country. 
 
Prevalence of HIV in Tamilnadu is 0.33% as on 2012
13,14
. 
 
 
 
 
 
 
 
HUMAN IMMUNODEFICIENCY VIRUS 
Human immunodeficiency virus
15
 (HIV) belongs to the genus lentivirus. 
Classified under the Retroviridae family it is a single stranded RNA virus. HIV 
causes acquired immunodeficiency syndrome (AIDS), a condition characterised 
by progressive failure of the immune system. 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC STRUCTURE OF HIV VIRION 
 
 
 
 
 
 
Shape
16
: spherical enveloped virus 
Size: 90-120nm 
Nucleocapsid: has an outer icosahedral shell and inner cone shaped core that 
which encloses ribonucleoproteins. 
Genome: diploid composed of two identical single stranded positive sense RNA 
copies. Bound to viral RNA is the reverse transcriptase enzyme.10 -15 in 
numbers. Also contains integrase enzymes and transfer RNA. 
 
 
VIRAL GENES AND ANTIGENS: 
STRUCTURAL GENES: 
These are the gag, pol, env; the products of which are the viral antigens
17
. 
1. gag: precursor proteins that determine the core and the shell of the 
virus.(p15, p18, and p24).   
p24 helps in disease detection and indications re-exacerbation. 
2. env: determines synthesis of envelope glycoprotein gp120 and gp 41. 
                                      gp120- forms surface spikes
17
. 
                                      gp 41 -forms the trans membrane anchoring   
                                                    protein
18
. 
3. pol :codes for polymerase reverse transcriptase ,protease and 
endonuclease 
 
NON-STRUCTURAL AND REGULATORY GENE: 
1. tat (trans activating gene): enhances expression of all viral  
          genes. 
2. nef (negative factor gene) : down regulates viral replication. 
3. rev (regulator of virus gene ): enhances expression of structural 
proteins. 
4. vif (viral infectivity factor gene): influencing infectivity of viral 
particles. 
5. vpu (HIV1) and vpx(HIV2) : enhancing maturation and release of 
progeny virus 
6. vpr stimulating promoter region of the virus. 
7. LTR (long terminal repeat)19 sequences, one at either end, containing 
sequences giving promoter, enchancer and integration signals. 
 
 
 
 
 
ANTIGENIC VARIATIONS: 
HIV has been characterized into HIV-1 and HIV-2
20
. 
HIV1: responsible for majority of infection. It is more virulent of the two. Three 
main are Group M (majority of cases), Group O and Group N.  
HIV2: largely confined to West Africa because of its low virulence. 
 
VIRUS STABILITY: 
HIV is thermolabile
21
, being inactivated in 10 minutes at 60 ˚C and in seconds at 
100 ˚C.  In dried blood it may survive for up to seven days. It withstands 
lyophilisation. 
HIV is inactivated in 10 min by treatment with 50% ethanol, 35% isopropanol, 
0.5% lysol, 0.5% paraformaldehyde, 0.3% hydrogen peroxide, 10% household 
bleach.Treatment of contaminated articles is with 2% solution of 
glutaraldehyde
22
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 AND HIV 
CD is an abbreviation of the cluster of differentiation /cluster of designation
23
. 
They are a defined sub classification of cellular surface receptors (> 250 in 
number), also called epitope; which identify cell type and stage of differentiation. 
These receptors coat the surfaces of the B and T lymphocytes and are recognized 
by antibodies. Of all the epitopes classified CD4 receptor present on the T 
lymphocytes has been in limelight for its highest association with HIV 
pathogenesis. 
 
CD4 is a membrane glycoprotein present on precursor T cells and also on a few 
mature T cells. Being a helper cell, when activated in presence of an infecting 
agent (antigen) triggers a cascading event thereby activating the co immune cells 
especially the killer T cells (CD 8) thereby eliminating the antigen
24
. 
 
HIV gains its entry into host immune system by attaching itself to CD4 surface 
receptor. Once infected by HIV there is a progressive depletion of both HIV 
infected and un-infected immune cells. The infected cells undergo programmed 
cell death by Fas mediated apoptosis
25
. The un-infected bystander immune cells 
undergo leaking HIV protein induced cell death, activation induced cell death 
(AICD), and cytokine mediated cell death. All the factors stated above results in 
failure of immune system. 
CD4+ T cell count in HIV infected individuals categorises the systemic/ 
opportunistic manifestations. CD4 cell counting includes various techniques of 
which flow cytometry
26
 is essentially used. CD4 values ranging from 500-1200 
cells/mm3 is considered normal range for HIV infected person. A fall below 
500cells/mm3 warrants frequent monitoring, and a fall below 350cells/mm3 
necessitates start of antiretroviral therapy.   
 
However a child is born with a very high level of CD4 (several thousands) and 
this cannot be used in monitoring disease. Therefore CD4 percentage in relation 
to other immune cells is used
27
. 
CD4% of 12-15%     = <200 cells/mm3, 
CD4% of 29%          = > 500 cells/mm3, 
CD4% of about 40% = HIV negative34.  
For treatment purposes in HIV infected child World Health Organisation 
recommends the following
28
: 
AGE  Infants and 
children <24 
months of age 
≥24 months of 
age to 59 months 
of age 
Five years of age 
or  
Older 
%CD4+  Absolute 
lymphopenia 
≤25  NA 
Absolute CD4 
count 
Absolute 
lymphopenia 
≤750 cells/mm3 ≤350 cells/mm3 
(As in adults) 
 
 
HIV TRANSMISSION 
 
TYPES OF EXPOSURE CHANCE OF INFECTION 
PER EXPOSURE 
Sexual intercourse: anal , vaginal , oral 0.1 – 1.0 % 
Blood and blood products, blood 
transfusion 
> 90% 
Tissue and organ donation: semen , 
cornea, bone marrow, kidney etc 
50 -90% 
Injections and injuries: injection with 
unsterile syringes, drug addicts shared 
needles, needle stick injury , surgical 
wounds 
0.5 -1.0% 
Mother to baby :trans-placental , at birth , 
after birth breast milk 
30% 
 
SEXUAL TRANSMISSION: 
Predominant mode of transmission. Risk of transmission increases with multiple 
sexual partners
29
. People indulged in riskful sexual practices. These people and 
their partners should be counselled regarding safer sex methods. 
 
BLOOD AND BLOOD PRODUCTS: 
Second important mode of transmission
30
. Major mode of transmission prior to 
recognition of HIV. Now with blood screening made mandatory the risk is 
reduced considerably. 
 
 
 
ORGAN TRANSPLANTATION: 
Organs are now screened for HIV and risk of transmission has been drastically 
reduced. This is applicable for semen, cornea, bone marrow, kidney and other 
organs. 
 
INJECTIONS: 
Relevant in intravenous drug abusers who share needles
31
. Also in medical and 
health professional the danger of needle stick injury persists to a great extent, 
though the chance of infection is much less. 
 
MOTHER TO CHILD: 
Child can be infected transplacentally
32
, during birth or with breast feeding. 30% 
of the infection occurs in utero and 70% during or after delivery. 
 
 
 
 
 
 
 
 
 
 
PATHOGENESIS 
HIV infects the host system, integrates its provirus into host cell genome
33
, 
activates viral replication thereby producing and releasing infectious virus 
.Gp120 of the virus binds to the CD4 receptor present on the T lymphocytes. The 
co receptors
34
 namely CCR5 and CXCR4 are equally important for virus entry 
into the cell for R5 and X5 strain of HIV respectively. Gp120 binding brings 
about conformational changes in Gp41, thereby allowing membrane penetration 
and fusion for viral membrane with host cell membrane.  
 
 
 
 
 
 
This is followed by entry of viral genome into cytoplasm. Once in the host 
cytoplasm HIV RNA undergoes reverse transcriptase mediated proviral DNA 
synthesis. HIV proviral DNA now integrates with host genome, and undergoes 
transcription and synthesis of HIV protein. Virion core structure assembly takes 
place. These core structures bind to host cell membrane followed by budding and 
release of mature virion. Multiple new virions are released in this process. These 
new virions in turn infect new host cells and the entire cycle of replication and 
release continues. This vicious cycle ultimately leads to irreparable deterioration 
of immune system. 
 
 
 
 
 
HIV CASE DEFINITION AND CLASSIFICATION 
PROVISIONAL DIAGNOSIS FOR AIDS, WHO: (1986)
36 
Presence of at least two major signs along with one minor sign, from those listed 
below 
 
MAJOR SIGN 
Weight lose greater than 10% of body weight 
Fever for more than one month, intermittent or continuous 
Chronic diarrhoea for more than one month, intermittent or continuous 
MINOR SIGN 
Persistent cough for more than one month 
General skin manifestation 
Recurrent herpes zoster 
Oropharyngeal candidiasis 
Chronic progressive and disseminated herpes simplex infection 
Generalised lymphadenopathy 
 
 
CDC CLASSIFICATION SYSTEM FOR HIV DISEASE: (1986) 
     Group I: acute infection 
     Group II: asymptomatic infection 
     Group III: persistent generalised lymphadenopathy 
     Group IV: other diseases 
 
        Subgroup A   constitutional disease 
        Subgroup B   neurologic disease 
        Subgroup C   secondary infectious disease 
        Subgroup D   secondary cancers 
        Subgroup E   other conditions 
 
 
 
 
 
Revised CDC classification of 1995 
 
 
Stage 1(HIV 
infection) 
CD 4 t lymphocyte count greater than or equal to 
500 cells/Ml 
Stage 2(HIV 
infection) 
CD4 T lymphocyte count of 200-499 cells/uL 
Stage 3 (AIDS) CD4 T lymphocyte count of less than 200 
cells/uL 
 
 
 
WHO STAGING: 
 
HIV-ASSOCIATED 
IMMUNODEFICIENCY 
        AGE RELATED CD4 VALUES IN % 
<11 
months 
12-35 
months 
36-59 
months 
>5 years 
None or not significant >35 >30 >25 >500 
Mild 30-35 25-30 20-25 350-499 
Advanced 25-29 20-24 15-19 200-349 
Severe <25 <20 <15 <200 or 
15% 
 
 
 
 
 
 
 
 
LABORATORY DIAGNOSIS 
Test includes for immunodeficiency as well as specific test for HIV. 
Specific test for HIV
37 
1. Antigen detection: p24 is the earliest virus marker to occur and 
detected by ELISA. 
2. Polymerase chain reaction: sensitive and specific test. DNA PCR and 
RNA PCR are the tests performed. The tests are complex and costly 
and indicated only when other tests do not give definitive results. 
3. Virus isolation: From peripheral lymphocytes. Patient’s lymphocytes 
co cultivated with uninfected lymphocytes in presence of interleukin -
249. 
4. Antibody detection: two type of tests- screening and confirmatory 
                            ELISA: screening test. Simple, inexpensive but false   
                            positives are common. 
                            WESTERN BLOT: it’s a gold standard confirmatory                              
                            test.             
 
Immunological tests: 
1. Total leucocyte and lymphocyte count 
2. CD4 cell count 
3. Platelet count 
4. Raised IgG and IgA level 
5. Lymph node biopsy 
ANTIRETROVIRAL THERAPY 
Standard antiretroviral therapy (ART)
38
 consists of the combination of at least 
three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop 
the progression of HIV disease. 
 
Various antiretroviral drugs approved for therapeutic use in India: 
NRTI NNRTI Protease 
inhibitor 
Entry 
inhibitors 
Integrase 
inhbitors 
Zidovudine  
Stavudine 
Lamivudine  
Abacavir 
Didanosine  
Tenofovir  
Dideoxycytidine 
Nevirapine  
Efavirenz 
Etravirenz 
Delaverdine                                               
Saquinavir  
Indinavir 
Ritonavir  
Nelfinavir
Lopinavir  
Atazanavir  
Darunavir                                 
Fos-
Amprenavir  
Tipranavir  
Enfuvitride 
Maraviroc  
 
Raltegravir  
NRTI : nucleoside reverse transcriptase inhibitor; 
NNRTI: non-nucleoside reverse transcriptase inhibitor 
 
Highly active antiretroviral therapy (HAART) is the combination of two or more 
groups of drugs that acts at different level of viral replication thereby increasing 
patient compliance and also decreasing chances of drug resistance. HAART is 
initiated when the CD4 count <350/uL, the combination depending on patient 
health status and other co morbidities. 
 
Most current HAART regimens consist of three (3) drugs: 2 NRTIs + a 
PI/NNRTI/II 
OCULAR COMPLICATIONS OF ANTIRETROVIRAL THERAPY 
Given below are the common drug used in our set up and its side effects; 
 
NRTI ADVERSE EFFECT 
Zidovudine Amblyopia, macular edema, 
photophobia 
Stavudine - 
Lamivudine Red itchy eye 
Abacavir Red itchy eye 
Tenofovir - 
didanosine Retinal changes, optic neuritis 
 
 
NNRTI ADVERSE EFFECT 
Nevirapine Red itchy eye 
 
 
PROTEASE INHIBITOR ADVERSE EFFECT 
Saquinavir blepharitis, dry eye syndrome, eye 
irritation, xerophthalmia, 
cytomegalovirus retinitis 
Indinavir Ocular pain , orbital edema 
Ritonavir Iritis , visual field defects, abnormal 
EOG 
Nelfinavir Acute iritis 
 
 
 
 
 
 
 
HIV IN OPHTHALMOLOGY 
CORRELATION OF CD4 T LYMPHOCYTE COUNT AND OCULAR 
LESION
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Stage Seroconversion63 Early 
infection 
Intermediate 
infection 
Late 
infection 
CD4+ 1000 500-1000 200-500 <200 
External 
eye 
Inflamed 
conjunctiva, Dry 
eye 
Allergic 
conjunctivitis 
Dry eye, 
Blepharitis, 
Bacterial 
andfollicular 
conjunctivitis, 
Kaposi’s 
sarcoma, 
Molluscum 
contagiosum, 
Opportunistic 
infections 
and tumours 
affecting all 
ocular 
structures 
Anterior 
segment 
 Reiters 
syndrome 
Intermediate 
uveitis 
 
Herpes 
simplex, 
Herpes zoster 
Posterior 
segment 
 HIV 
retinopathy 
Retinal 
vasculitis 
 
HIV 
retinopathy, 
Tuberous 
uveitis 
Neuro 
ophthalmic 
Headache Retro 
orbital pain 
Optic 
neuropathy 
Aspergillosis 
 
 
 
 
 
 
 
SITE WISE OCULAR LESION IN AIDS: 
 
 
 
SITE LESIONS  
ADNEXA Herpes zoster ophthalmicus 
Kaposi sarcoma 
Molluscum contagiosum 
Eyelid infections 
Allergic or infective conjunctivitis 
ANTERIOR SEGMENT Dry eye 
Infective keratitis 
Uveitis 
Microvasculopathy 
POSTERIOR SEGMENT HIV retinopathy 
CMV retinitis 
Progressive outer retinal necrosis 
Acute retinal necrosis 
Fungal endophthalmitis 
Toxoplasma retinochoroiditis 
Ocular syphilis 
Mycobacterium infection 
ORBIT Orbital cellulitis 
Burkitts lymphoma 
NEURO OPHTHAL Cranial nerve palsies 
Papilledema 
Optic neuropathy 
 
 
 
 
 
 
 
 
DESCRIPTION OF HIV OCULAR LESIONS 
EYELID INFECTIONS
 
Blepharitis and meibominitis are common adnexal presentations and require 
prompt treatment which includes lid hygiene, hot fomentation and support 
antibiotics. 
 
MOLLUSCUM CONTAGIOSUM 
HIV infected patients have an extensive, coalescing lesions and these recur on 
treatment. Treatment includes cautery- electrical or chemical, surgical excision. 
 
KAPOSI SARCOMA (eyelid and conjunctiva) 
A vascular lesion, reddish purple in colour arising from the lid and or 
conjunctiva. Usually said to be associated with herpes virus 8 infections. Kaposi 
sarcoma in HIV has not been reported in Indian context. 
 
CONJUNCTIVAL MICROVASCULOPATHY 
AIDS virus is said to directly attack the vascular wall leading to its dilation/ 
segmentations, and cock-screwing. 
 
HERPES ZOSTER OPHTHALMICUS 
5- 15% of HIV population will have varicella zoster infection associated with 
keratitis, uveitis, scleritis, and retinitis. Atypical presentation with bilateral 
involvement is commonly seen. Treatment is with acyclovir given intravenous 
and oral for maintainance. 
INFECTIVE KERATITIS 
HIV individuals are easily susceptible to corneal infection from bacterial, viral, 
fungal and protozoal. 
 
UVEITIS 
Unexplained uveitis in an individual should prompt investigations for HIV. 
Uveitis in HIV-infected patient should prompt a search for an underlying 
infection, including tuberculosis, syphilis, histoplasmosis, coccidioidomycosis, 
and toxoplasmosis. 
 
HIV RETINOPATHY  
It is a non-infectious microvascular disorder of the retina in HIV infection. With 
cotton wool spots, microaneurysms retinal haemorrhages and capillary non 
perfusion this almost mimics diabetic retina. Therefore it becomes a necessity to 
rule out HIV in unexplained vascular occlusive diseases.  
 
The virus is said to deposit on the vascular endothelium thereby inciting an 
antigen antibody mediated immune reaction leading to vascular necrosis and 
secondary ischemia. Cotton wool spots are more commonly seen than 
haemorrhages due to the above mentioned reason. 
 
Hemorrhages are seen less commonly seen than cotton-wool spots.They may 
involve both the nerve fiber layer and the deeper retina and may appear as flame-
shaped, dot, or blot hemorrhages. 
 
CYTOMEGALOVIRUS RETINITIS 
Is the most common opportunistic infection in HIV. Cytomegalovirus is a DNA 
herpes group virus occurring in advanced HIV disease. This DNA virus invades 
the retinal cells causing retinal necrosis. Manifests either in indolent or fulminant 
form. The indolent variety has granular white retinal deposits, has minimal or no 
vasculitis and no retinal hemorrhage. The fulminant type presents with retinal 
deposits, vasculitis and haemorrhages. Both varieties begin in the periphery and 
spread to centre along the vascular arcade leading to triangular / wedge zones. 
Vitritis if at all will be minimal. Frosted branch angiitis in another mode of 
presentation. With eventual loss of retinal pigment epithelium the underlying 
choroidal vasculature becomes prominent. 
 
Treatment includes both systemic and intravitreal injections of gancyclovir. 
Other drugs include valcyclovir, foscarnet. Administer till lesion heals. Retinal 
detachment can be a major challenge while treating CMV retinitis. 
 
ACUTE RETINAL NECROSIS 
Rapidly progressing bilateral viral uveitis in immunocompromised patient caused 
most commonly by Varicella followed by herpes or CMV.bilateral involvement 
is common with complications like retinal detachment and proliferative 
vitreoretinopathy. Ganciclovir /foscarnet, with adjunctive high-dose intravenous 
acyclovir (15 mg per kilogram every 8 hours)is the treatment of choice. 
 
 
TOXOPLASMA RETINOCHOROIDITIS 
Protozoan parasite which exists in cyst and trophozoites form. Though the 
infection occurs in early in extremely immunocompromised person, the ocular 
manifestation occurs usually on immune recovery on administration of HAART. 
This is because the immune mediated reaction is directed towards the cyst which 
is severe. In HIV, toxoplasmosis is characterised by multifocal retinochoroidal 
fluffy lesions involving entire retina with severe vitritis. Degree of haemorrhage 
is less in comparison to CMV retinitis. Fluorescein angiography differentiates 
toxoplasmosis from CMV retinitis by active leakages. 
 
Serological testing for toxoplasma in HIV is unreliable. They either show low 
IgG titres or are unable to distinguish old from new lesions. Negative IgG titre 
however makes it unlikely for toxoplasma infection to be present. 
Standard dosage treatment with pyrimethamine, sulfadiazine or clindamycin is 
said to be sufficient. Treatment is continued till the normal range of CD4 is 
achieved for HIV patients. 
 
 
 
PNEUMOCYSTIS CHOROIDITIS: 
Pneumocystis jiroveci (PCP), is a fungus showing protozoal characteristics. It 
presents as multiple yellow white choroidal lesions, generally round and of 
variable size. It eventually leads to choroiadal necrosis. The earliest evidence of 
PCP retinal infection was seen in 1982, where the histopathological report 
showed evidence of PCP in ganglion and plexiform layer of retina. In 1987 
histopathologic examination revealed areas of choroidal thickening and exudate 
which harbored the characteristic cysts of P jiroveci in HIV patients. Treatment 
will be same as for respiratory PCP infection. 
 
SYPHILIS 
Syphilitic presentations include perivasculitis, hemorrhages, chorioretinitis , 
panuveitis and papillitis. These patients manifest symptomatic neuroshyphilis. 
Lumbar puncture is the current recommendation for ocular syphilis in HIV to 
rule out neurological involvement. The serum fluorescent treponemal antibody 
absorption test (FTA-ABS) is the most reliable laboratory studies for diagnosing 
ocular syphilis. Syphilis runs a rapid aggressive course in HIV-infected patients 
than in immunocompetent individuals. 
 
 
 
 
 
OPTIC DISC 
Optic disc involvement includes papilledema as a result of intracranial space 
occupying opportunistic lesions, optic neuritis or neuropathy. 
Optic neuritis in HIV is either a primary HIV manifestation or a secondary 
opportunistic manifestation. HIV is said to have a direct cytotoxic effect on 
axonal cells causing inflammation of optic nerve and death. Eventually optic 
atrophy ensues
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TREATMENT OF OCULAR HIV MANIFESTATIONS 
LID INFECTIONS: 
Lid hygiene is of utmost importance. Antibiotics ointment and oral antibiotics are 
necessary. Also strict adherence to antiretrpviral therapy helps to maintain good 
immunity. 
 
MOLLUSCUM CONTAGIOSUM: 
Strict ART follow up. Topical trichloroacetic acid can be applied. Surgically 
curettage,excision or cryotheraphy can be done. 
 
CONJUNCTIVITIS: 
Infective conjunctivitis needs to be proved on grams stain and culture, and 
treated accordingly. 
If allergic the drug causing should be replaced and symptomatic topical 
medication like lubricating drops applied. 
 
CONJUNCTIVAL MICROVASCULOPATHY: 
This finding has no treatment. 
 
HERPES ZOSTER OPHTHALMICUS: 
Acyclovir 10 milligram per kilogram of body weight administered IV every 8 
hours for 1 week.  Maintenance dose of oral acivir 800mg, 3-5 times a day 
indefinite. 
On follow up patient had to be treated for post herpetic neuralgia if sny. 
Alternatives include valacyclovir. 
 
VIRAL KERATITIS:  
If the cause is varicella zoster, oral acivir 800mg 5 times a day is given. For 
resistant cases IV foscarnet has been useful. Topical trifluridine 1 percent is also 
seen to be helpful in controlling varicella keratitis. 
If the cause is herpes zoster; same treatment as for varicella. Topical application 
of antiviral medication is most indicated in herpes keratitis as it tends to recur 
more frequently in HIV AIDS patients. 
 
FUNGAL AND BACTERIAL KERATITIS: 
Treatment depends on the culture sensitivity and grams stain reports. Strict 
adherence to both ocular medication and antiretroviral therapy ensures a quick 
healing.  These patients go in for perforations easily and needs a strict follow up. 
 
UVEITIS: 
Usually drug induced, treatment consists of topical steroids tapered over weeks 
till resolution. 
 
GLAUCOMA: 
Usually of the inflammatory component, the underlying cause has to be treated 
first and also topical anti glaucoma medication have to be administered taking 
care to avoid prostaglandin analogue. 
 
HIV RETINOPATHY: 
Immune status needs to be evaluated and patient followed up every 3 months for 
dilated fundus examination. 
 
CMV RETINITIS: 
Ganciclovir 5mg/kg IV, 12
th
 hourly for 3 weeks. Followed by maintenance doses 
of 5mg/kg/day is given twice weekly until lesion is inactive. 
Alternate drugs include foscarnet and valganciclovir.  
Immune status has to be improved with strict adherence to HAART. If the patient 
has never been on HAART prior to the occurrence, regime can be postponed to 
prevent immune recovery uveitis. 
Patient needs to be educated about the recurrence and must be advised for a serial 
follow for dilated fundus examination. 
 
TOXOPLASMOSIS: 
Trimethoprim/ sulfamethoxozole 400mg administered per oral twice a day for 4 
to 6 weeks. 
Patients with very low immunity have to be given at least one drug life time or 
till immune status improves. 
 
ACUTE RETINAL NECROSIS/ PROGRESSIVE OUTER RETINAL 
NECROSIS: 
Intravenous 15mg/kg acyclovir is given 8th hourly. Foscarnet or Valcyclovir 
could be prescribed alternatively. Patient needs to be monitored for drug induced 
complications. Usually progresses rapidly. 
 
MULTIPLE CRANIAL NERVE PALSY: 
Find the underlying cause and treat. 
OPTIC NEURITIS: 
Underlying cause has to be found and treated. 
 
OCULAR TUBERCULOSIS: 
Rifampicin 500mg/kg, isoniazid 5mg/kg, pyremethamine 30 mg/ kg, ethambutol 
15mg /kg; for a duration of two months and followed by rifampicin and isoniazid 
for remaining 4 to 7 months depending on patient’s response to medication.40 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
                     PART II 
  
AIM 
 To evaluate the prevalence of ocular manifestations in HIV seropositive 
patients, attending the ART centre, Stanley Medical College and Hospital. 
 
 To evaluate how the manifestations correlate to the CD4 count. 
 
 To evaluate the impact of HAART on ocular HIV manifestations. 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS AND MATERIAL 
STUDY DESIGN:  
 Cross sectional study was undertaken on 100 HIV seropositive patient 
attending the ART centre with known CD4 count was included in the 
study. 
 The study period was from February 2013 till completion of hundred 
patients.  
 
INCLUSION CRITERIA 
 HIV seropositve consented patients attending ART centre irrespective of 
ocular complaints, irrespective of treatment status. 
 Any age group  
 CD4 count obtained at the time of examination. 
 
EXCLUSION CRITERIA 
 Severely ill patients. 
 CD4 count could not be obtained. 
 Pre-existing systemic illnesses. 
 
 
 The importance of ocular examination in them was thoroughly explained 
in patients own language. 
 Consent in patients own language was obtained from all those who were 
willing to take part in study. 
 Any photographic records of the lesions were taken only if the patient 
consented for the same. 
 Upon completion of data collection, statistical analysis was applied. 
 
STATISTICAL ANALYSIS: 
 Chi square test was done for statistical analysis of the obtained data. 
 
 
 
 
 
 
 
 
 
ROUTINE OCULAR EXAMINATION WAS DONE AS FOLLOWS: 
 Ocular history. 
 Ocular examination included: 
     Best corrected visual acuity. ( Snellen’s chart ) 
          Slit lamp evaluation – Adnexa and Anterior segment  
         Dilated fundus evaluation(0.8 % tropicamide + 5% phenylephirine)90 D       
                                                     and 20 D 
        Neuro ophthalmological examination 
        Orbit  
        Tonometry for IOP evaluation 
        Schirmer’s for dry eye evaluation 
 
 Patient with suspected lesions were referred for complete systemic and 
laboratory work up. 
 Serological investigations included TORCH titre, PCR assay for HZV, 
VZ. 
 Other investigations were done as per clinical indication included CT 
brain/ MRI brain. 
OBSERVATIONS 
This study includes 100 consented HIV seropositive patients, irrespective of age 
or gender, provided CD4 count was available at the time of ocular examination. 
 
AGE WISE DISTRIBUTION: N = 100 
Table 1 
AGE IN YEARS NO OF PATIENTS 
<20 5 
20-40 58 
40-60 34 
>60 3 
 
 
 
 The overall average age of the study population was 38.14 years. 
 
 The reproductive age group of twenty to forty years formed the major part 
of our study, with 58 patients falling under this group.  
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 Of these fifty-eight patients, forty-three fall under age group of thirty-one 
to forty years. 
 
 In the age group less than twenty years, 5 children were observed. The 
average age is 9 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENDER DISTRIBUTION: N= 100 
With no attempt to maintain an equal count of the gender population, we 
observed 59% males and 41% females. 
Table 2 
GENDER NO OF PATIENTS 
MALE 59 
FEMALE 41 
 
 
 
 
AGE DISTRIBUTION OF GENDER WAS AS OBSERVED BELOW: 
Table 3 
AGE 
GENDER 
MALE FEMALE 
<20 2 3 
20-40 32 26 
40-60 22 12 
>60 3 0 
 
 The age of the male patients ranged from thirteen to seventy-seven years. 
Whereas age of female patients ranged from four to fifty-seven years. 
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  The mean age for the fifty nine male patients is 39.7 years. And for the 
forty-one female patients is 35.9 years. 
 
 
Table 4 
GENDER 
NO OF 
PATIENTS 
AVERAGE 
AGE 
STD 
DEVIATION 
  
( MEAN) FOR AGE P value 
MALE 59 39.7 11.75 
0.303079 
FEMALE 41 35.9 11.27 
 
 Upon statistically validating the age – gender distribution using chi square 
test, we arrived upon a p value of 0.303079. 
  
 Hence this shows that the given gender distribution for age did not affect 
the overall study. 
 
 
 
 
 
 
 
 
 
 
OCCUPATION: N = 100 
 
Table 5 
OCCUPATION NO OF PATIENTS 
SKILLED 17 
UNSKILLED 79 
UNEMPLOYED 4 
TOTAL 100 
 
 
 
 
 AGE WISE OCCUPATION DISTRIBUTION: 
Table 6 
AGE 
OCCUPATION 
SKILLED  UNSKILLED  UNEMPLOYED 
<20 0 5 0 
20-40 11 46 1 
40-60 6 27 1 
>60 0 1 2 
Chi Test =0.000015, Df= 6 
P value= 0 
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 79 Unskilled workers formed a major part of our study, with 46 of them 
falling under the reproductive age group. Majority of these unskilled 
workers were drivers. 
 The 5 children were included under the unskilled group. 
 
 The 11 skilled workers, including  businessmen also were of the 
reproductive age group. 
 
 There is a high prevalence rate of disease amongst the unskilled workers 
and is statistically proved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MARITAL STATUS: N= 100 
Table 7 
MARITAL STATUS NO OF PATIENTS 
SINGLE 8 
MARRIED 90 
WIDOWED 2 
TOTAL 100 
 
 
 
 
 90 out of the 100 patients in our study were married and contracted 
disease either from multiple sexual partners or from the exposed spouse. 
 
 Interestingly 1 widow was diagnosed with the disease following death of 
the male spouse from undiagnosed illness. 
 
 The single group of 8 people included 5 children and 3 unmarried adult 
males. 
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MODE OF DISEASE EXPOSURE: N = 100 
Table 8 
MODE OF DISEASE EXPOSURE NO OF PATIENTS 
SEXUAL 91 
BLOOD TRANSFUSION 2 
INJECTIONS 2 
MTC 5 
TOTAL 100 
 
 
 We observed that Sexual exposure was the most common form of disease 
transmission, with all 91 patients having had heterosexual exposure. 
 
 5 children had vertical transmission of the disease from the exposed 
mother  (mother to child transmission/ MTC). 
 
 4 patients amongst the reproductive age group had non sexual exposure. 
Two of which had history of blood transfusion in the recent past, and 2 
had high risk IV drug abuse behaviour with needle sharing. 
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WHO CLINICAL STAGE: N = 100 
Table 9 
WHO CLINICAL STAGE NO OF PATIENTS 
I 73 
II 7 
III 10 
IV 10 
TOTAL 100 
 
 
 
Table 10 
WHO CLINICAL STAGE 
OCULAR LESION 
TOTAL 
PRESENT ABSENT 
I 54 19 73 
II 7 0 7 
III 8 2 10 
IV 9 1 10 
TOTAL 78 22 100 
P Value = 0.003 
 
 WHO clinical stage I consisted of 73 patients, indicating that the patients 
were asymptomatic or had acute flu like symptoms on disease detection. 
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 The 20 patients from clinical stage III and IV were all diagnosed with HIV 
following systemic illnesses that should be presumed to be due to 
immunocompromised state. 
 
 One patient had esophageal candidiasis, four patients had recurrent viral 
infections, two had protozoal infections, two had intra cranial space 
occupying lesions (One expired during follow up, one diagnosed with 
tumefactive demyelination due to HIV infection), four patients had 
tuberculosis and the remaining seven patients had HIV wasting syndrome.  
 
 Nine out of these twenty patients had HIV associated severe ocular 
manifestations. Interestingly one patient, a child of four years of age, in 
clinical stage IV (extra pulmonary TB) of age did not exhibit any ocular 
lesion and her CD4 count was 2149. 
 
 The association of severe opportunistic ocular infection in WHO clinical 
Stage III/IV therefore has been statistically verified. 
 
 
 
 
 
 
CD4 COUNT DISTRIBUTION: N = 100 
 In our study we had CD4 count ranging from 28 – 2149 cells/mm3. 
 The average CD4 count therefore was 503.57 cells /mm3. 
Table 11 
CD4 COUNT  NO OF PATIENTS 
<200 11 
201 – 500 45 
>500 44 
 
 
Table 12 
CD4 COUNT 
AGE DISTRIBUTION 
TOTAL 
<20 20-40 41-60 >60 
<200 0 7 3 1 11 
200-500 3 29 12 1 45 
>500 2 22 19 1 44 
TOTAL 5 58 34 3 100 
 
 Eleven patients were severely immunocompromised with CD4 count of < 
200 cells/mm3. 
 
 Note that none of the children observed in our study were severely 
immunocompromised. All five children maintained CD4 count > 200.  
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DURATION OF THE HIV DISEASE: N = 100 
Table 13 
DURATION SINCE DISEASE 
DETECTION (MONTHS) 
NO OF PATIENTS 
<12 13 
13-24 45 
25-60 36 
>60 6 
TOTAL 100 
 
 
 
 
 We observed patients with disease duration ranging from as early as 2 
months up to 9 years. 
 
 The average duration of disease being 4.03 years. 
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HAART REGIME: N = 100 
 
Table 14 
PATIENTS ON HAART NUMBER 
YES 85 
NO 15 
 
 
 
 
 
 
 
 
 
 
 HIV seropositive patients detected with CD4 count of < 350 /mm3 at any 
point; at or later date to disease detection were started on HAART regime 
as per WHO recommendations. 
 
 Fifteen patients were on observation with half yearly CD4 re-evaluation 
and treated symptomatically. 
 
 Eighty-five patients were on HAART regime, which was initiated as per 
WHO recommendation, and as per patient’s systemic associated 
conditions and response to drugs.  
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DURATION SINCE HAART TREATMENT: N = 85 
 
Table 15 
DURATION SINCE STARTING HAART (MONTHS)  NO OF PATIENTS 
<12 15 
13-24 17 
25-60 47 
>60 6 
TOTAL 85 
 
 
 
Table 16 
DURATION SINCE 
STARTING HAART 
OCULAR LESION  
TOTAL 
PRESENT ABSENT 
<12 12 3 15 
13-24 12 5 17 
25-60 38 9 47 
>60 5 1 6 
TOTAL 67 18 85 
Chi Test = 0.827356 , Df =3 
P value= 0.2399 
 
 Sixty-seven out of the eighty-five patients on HAART manifested ocular 
lesions in various forms.  
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 Majority of the lesion were found in time duration of two to five years of 
HAART regime.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TB STATUS: N = 100 
Table 17 
SYSTEMIC TB STATUS NO OF PATIENTS 
CURRENT  6 
PAST  25 
NIL 69 
TOTAL 100 
 
 
 
 
 Six out of hundred patients were recently diagnosed and currently under 
treatment for tuberculosis. Two of these were children of age less than 
fourteen.  
 
 
 Twenty-five patients were treated for tuberculosis in the past, in the time 
frame of HIV detection- duration, of which one was a child. 
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OCULAR SYMPTOMS: N = 100 
 
Table 18 
OCULAR SYMPTOMS NO OF PATIENTS 
PRESENT 30 
ABSENT 70 
 
OCULAR FINDINGS: N = 100 
Table 19 
OCULAR FINDINGS NO OF PATIENTS 
PRESENT  78 
ABSENT 22 
 
 
 Seventy-eight out of the hundred patients that we examined had findings 
from the adnexa up to the optic nerve. The average CD4 count in these 78 
patients was noted to be 468.16. 
 
 These findings were either a manifestations of viral load, or of low 
immunity, and/ or of opportunistic infections. 
 
 The twenty-two patients those who dint have ocular findings had an 
Average CD4 count of 629.09. 
 
 
OCULAR SYMPTOMS VERSUS OCULAR FINDINGS: 
 
Table 20 
OCULAR FINDINGS 
OCULAR SYMPTOMS 
TOTAL 
PRESENT ABSENT 
PRESENT  29 49 78 
ABSENT 1 21 22 
TOTAL 30 70 100 
P value = 0.003178 
 
 Thirty HIV seropositive patients had ocular symptoms. Of these twenty-
nine patients almost all had severe blinding opportunistic manifestations. 
The remaining one patient had refractive error. 
 
 Amongst the remaining seventy patients who had no ocular symptoms 
HIV retinopathy was the most common finding.  
  
VISION DISTRIBUTION: 
The severity of manifestations on visual acuity was as observed below; 
Table 21 
VISION STATUS RIGHT EYE LEFT EYE BOTH EYES 
BLIND 3 2 1 
<3/60 1 3 2 
3/60- 6/60 1 0 0 
6/60- 6/18 2 2 2 
>6/18 93 94 87 
 
 Five out of hundred patients had ocular manifestations leading on to 
bilateral impairment in vision. Of which one patient was completely blind. 
 
 Nine out of hundred patients had unilateral vision impairing 
manifestations. 
 
 The patient with bilateral blindness was diagnosed with severe toxoplasma 
retinochoroiditis. 
 
 The remaining patients had manifestations like CMV retinitis, acute 
retinal necrosis, retinal vasculitis, retinitis, intermediate uveitis, viral 
keratitis, complicated cataract and non-healing fungal corneal ulcer. 
 
 
 
 
OCULAR FINDINGS IN OUR STUDY:  
 Seventy eight out of hundred patients had HIV related ocular 
manifestation. Majority of the patients in our study had multiple 
manifestations at the time of examination; blepharitis and conjunctival 
microvasculopathy were commonly found and accounting for the overlap 
in the total number of manifestations. 
Table 22 
OCULAR FINDINGS  NUMBER OF PATIENTS 
WITH FINDINGS 
  
 
PERCENTAGE 
ADNEXA  
BLEPHARITIS 29 24.79 
MOLLUSCUM CONTAGIOSUM 2 1.71 
STYE 2 1.71 
HERPES ZOSTER 1 0.85 
ALLERGIC / INFECTIVE  
CONJUNCTIVITIS 
6 
5.13 
CONJ. MICROVASULOPATHY 53 45.3 
ANTERIOR SEGMENT     
COMPLICATED CATARACT 1 0.85 
HERPES ZOSTER 
OPHTHALMICUS 
1 
0.85 
VIRAL KERATITIS 1 0.85 
ANTERIOR UVEITIS 1 0.85 
NON HEALING FUNGAL ULCER 1 0.85 
INFLAMMATORY GLAUCOMA 1 0.85 
POSTERIOR SEGMENT    
HIV RETINOPATHY  4 3.42 
CMV RETINITIS BURNT OUT 2 1.71 
ARN 1 0.85 
TOXOPLASMOSIS 2 1.71 
RETINAL VASCULITIS 1 0.85 
INTERMEDIATE UVEITIS 1 0.85 
RETINITIS  1 0.85 
NEURO OPHTHAL    
MULTIPLE CRANIAL NERVE 
PALSY 
1 
0.85 
OPTIC NEURITIS 1 0.85 
OPTIC ATROPHY 4 3.42 
ORBIT  NIL 
 
OCULAR FINDING AND AGE DISTRIBUTION: N = 78 
Table 23 
AGE IN YEARS NO OF PATIENTS WITH FINDINGS 
<20 3 
20-40 44 
41-60 29 
>60 2 
TOTAL 78 
 
 
 
 
 75.85 % of the ocular manifestation was seen in the age group of twenty 
to forty years (58 people).  
 
 However when checked for its significance (by chi square test), the age 
wise distribution of ocular lesion proved to be statistically insignificant. 
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GENDER WISE DISTRIBUTION OF OCULAR FINDINGS: N = 78 
 
Table 24 
GENDER NO OF PATIENTS AVERAGE CD4 COUNT 
MALE 44 432.32 
FEMALE 34 606.09 
 
 
 
 Forty-four out of these seventy-eight patients with HIV ocular 
manifestations were male when comparison to thirty-four females; who 
had disease manifestations. 
 
 The average CD4 count in the forty-four male patients with ocular 
manifestations was found to be 432.32. 
 
 The average CD4 count of 606.09 was observed in thirty-four  female 
patients with ocular manifestations. 
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OCULAR FINDING AND ROUTE OF EXPOSURE: N= 78 
Table 25 
MODE OF DISEASE EXPOSURE NO OF PATIENTS AVERAGE CD4 COUNT 
SEXUAL 73 602.8 
BLOOD TRANSFUSION 1 780 
INJECTIONS 2 261 
MTC 2 371.5 
 
 
 
 
 This data shows the prevalence of manifestations for various routes of 
transmission. 
 
 Injection/ IV drug abuse had 100% manifestations (though a non-blinding 
manifestation) when compared to blood transfusion which exhibited 50% 
prevalence of manifestation.  However this data is insignificant in terms of 
sample size. 
73 
1 2 2 
0
10
20
30
40
50
60
70
80
SEXUAL BLOOD
TRANSFUSION
INJECTIONS MTC
NO OF PATIENTS
 Ocular manifestations were more seen in patients with sexual mode of 
transmission. 
 
 Seventy-three of ninety-one (80%) were sexually exposed patients who 
exhibited ocular manifestations. 
 
 Most of the ocular blinding manifestations were observed to occur in 
patients exposed to HIV sexually, and this specific group had CD4 
ranging from 28- 1916 cell/mm3. And these in itself are manifestations of 
other associated sexually transmitted diseases. 
 
 The 2 patients, who contracted disease by the IV route, had CD4 counts of 
< 350 cells/mm3. 1 out of the 2 patients, who had been seen after a year 
showed just a minimal improvement in immunity. This probably indicates 
the high viral load transmission via injections/IV drug abuse. However 
none of the two had opportunistic manifestations. 
 
 Two of five children (40%) in our study group were observed to have 
manifested lesions. 
 
 
 
 
 
OCULAR FINDINGS AND WHO CLINICAL STAGING: N = 78 
 
Table 26 
WHO CLINICAL STAGE NO OF PATIENTS 
I 54 
II 7 
III 8 
IV 9 
TOTAL 78 
 
 
 
 Fifty-three out of the seventy-eight patients with ocular manifestation 
were observed under the clinical stage I of WHO classification. All 
patients in our study group with HIV retinopathy fell under this clinical 
staging of HIV. One patient with intermediate uveitis was under WHO 
clinical stage 1. 
 
 Clinical stage II we observed seven people. Of these two patients had 
molluscum contagiosum, two had herpes zoster ophthalmicus, one had 
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allergic conjunctivitis, one had non healing fungal corneal ulcer and one 
had microvasculopathy. 
 
 Seventeen patients from WHO clinical stage III and IV categorised under 
ocular manifestations had vision impairing opportunistic diseases. These 
included viral keratitis, CMV retinitis , toxoplasma retinochoroiditis, acute 
retinal necrosis, multiple cranial nerve palsy, optic neuritis etc. 
 
 The average CD4 count of patients from stage III and IV was 400.47 
cells/mm
3
. The lowest CD4 count being 28 cells and the highest being 
1043 cells/mm
3
. 
 
 
 
 
 
 
 
 
 
 
 
 
OCULAR FINDING AND CD4 COUNT: N =78 
 
Table 27 
CD4 COUNT  
OCULAR LESION 
% OF OCULAR LESION 
PRESENT ABSENT 
<200 10 1 90.90 
200-500 34 11 75.55 
>500 34 10 77.27 
 
 
 
 
 The prevalence of ocular manifestations is noted to increase with decrease 
in CD4 count which can be observed from the table above. 
 
 On the contrary, with the increase in CD4 count the prevalence of lesions 
were found to be decreasing which can be observed from the table above. 
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Table 28 
CD4 COUNT  
GENDER 
TOTAL 
MALE FEMALE 
<200 8 2 10 
200-500 21 13 34 
>500 14 20 34 
TOTAL 43 35 78 
 
 
 From the table above, we observed that the prevalence of male patient 
with ocular lesions is 80 % with the CD4 count < 200 cells/mm3. 
 
 In the group with CD4 count > 500 cells/mm3, female and male patients 
had a prevalence of 58.82% and 41.17% respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCULAR FINDINGS AND HAART REGIME DURATION: N= 78 
 
Table 29 
DURATION 
OF HAART 
TREATMENT 
 ( MONTHS) 
NUMBER 
OF 
OCULAR 
LESIONS 
MEAN AND STD. DEV CD4 COUNTS 
% 
INCREASE 
IN CD4 
COUNT 
BASE 
CD4 
STD 
DEV 
PRESENT 
CD4 
STD 
DEV. 
<12 12 315.33 194.64 314.66 217.31 -0.21 
13-24 12 324.58 271.2 461.76 272.21 29.71 
25-60 38 319.52 271.2 473.45 272.21 32.51 
>60 5 425.16 270.2 766.16 273.04 44.51 
 
Table 30 
DURATION SINCE HAART 
TREATMENT 
OCULAR LESION 
TOTAL 
PRESENT % ABSENT % 
<12 12 80 3 20 15 
 12-24 12 70.58 5 29.41 17 
25-60 38 80.85 9 19.14 47 
>60 5 83.33 1 16.66 6 
 
 When comparing the baseline CD4 count at the start of HAART to the 
CD4 count at the time of examination, we observed a significant increase 
in CD4 count, suggesting the effectiveness of HAART. 
 
 However we also observed an increase in ocular manifestations of HIV 
with increase in CD4 counts, while the patient was under HAART 
Regime. 
 
  
CORRELATING THE FINDINGS WITH CD4 COUNTS: N =156 EYES 
Table 31 
  CD4 COUNT DISTRIBUTION FOR N = 156 
ADNEXA <200 200-500 >500 
BLEPHARITIS 18 22 16 
MOLLUSCUM CONTAGIOSUM 0 4 0 
STYE 0 2 1 
HERPES ZOSTER 0 1 0 
ALLERGIC / INFECTIVE 
CONJUNCTIVITIS 
2 8 2 
CONJ. MICROVASCULOPATHY 19 34 52 
ANTERIOR SEGMENT        
COMPLICATED CATARACT 0 2 2 
HERPES ZOSTER 
OPHTHALMICUS 
0 0 1 
VIRAL KERATITIS 0 1 0 
ANTERIOR UVEITIS 0 0 2 
NON HEALING FUNGAL 
CORNEAL ULCER 
0 1 0 
INFLAMMATORY GLAUCOMA 0 0 2 
POSTERIOR SEGMENT       
HIV RETINOPATHY  0 6 1 
CMV RETINITIS BURNT OUT 0 0 3 
ARN 2 0 0 
TOXOPLASMOSIS 0 2 2 
RETINAL VASCULITIS 0 0 2 
INTERMEDIATE UVEITIS 0 0 2 
RETINITIS 2 0 0 
NEURO OPHTHAL       
MULTIPLE CRANIAL NERVE 
PALSY 
1 0 0 
OPTIC NEURITIS 1 0 0 
OPTIC ATROPHY 2 0 6 
 From the above tabular column the following observations are made: 
 Blepharitis was present in patients irrespective of the CD4 counts. 
 
 Conjunctival microvasculopathy was present in patients irrespective of 
CD4 counts.  
  
 CONJUNCTIVAL  MICROVASCULOPATHY 
 
 
 
 
 
RECURRENT BLEPHARITIS  
 
 
 
 
  Stye and molluscum contagiosum manifested in CD4 cell range of 200- 
500 cells. 
 
 Allergic conjunctivitis was observed in all ranges of CD4 counts. 
 
 Herpes zoster infection was seen to occur in CD4 of > 200 - < 1000 
cells/mm3. 
 
 Complicated cataract occurred respectively in patients with anterior 
uveitis and toxoplasmosis induced inflammatory anterior reaction in the 
respective CD4 cell ranges. 
 
 
 Keratitis, both viral and fungal manifested in the range of 200 – 500 
cells/mm3. Viral keratitis healed with patient’s strict adherence to 
treatment.  
           The fungal ulcer was non-healing and referred to higher centre for surgical       
           management. 
 
 A special mention on HIV retinopathy : Out of four patients with HIV 
retinopathy, three manifestations occurred when CD4 had fallen <500 
cells/mm3. One was observed to have manifested with CD4 of > 500 
cells/mm3. 
ANTERIOR UVEITIS WITH COMPLICATED CATARACT 
 
 
 
 
 
 
 
  
HEALED  HERPES ZOSTER 
 
 
 
 
 
FIELD DEFECTS IN PATIENT WITH TUMEFACTIVE 
DEMYELINATION OF BRAIN 
 
 
 
 It should also be noted that these patients with HIV retinopathy had 
associated conjunctival microvasculopathy. 
 
 The two patients we examined to have CMV retinitis, both females; had 
burnt out retina. And both these patients had their CD4 > 500 cells.  
This indicated a probable infection with CMV when severely 
immunocompromised, and healing of lesion with adequate treatment. 
 
 One patient presented to us with Acute Retinal Necrosis with a CD4 count 
of 28cells/mm3. The patient expired during follow up. 
 
 The intermediate uveitis was of unknown eitiology. All necessary 
investigation for TORCH and PCR for herpes and varicella came 
negative. Patient was not on any uveitis inducing drugs.  
          This probably was a case of HIV induced uveitis. 
 
 The patient with features of retinal vasculitis and no systemic 
manifestation of tuberculosis (CD4 of 1043 cells/mm3) failed to review 
with reports and therefore the laboratory diagnosis was incomplete. 
 
 Retinitis was seen in one patient involving both eyes with CD4 count of < 
200 cells / mm3. Patient was positive for toxoplasma gondii, herpes 
simples virus and cytomegalovirus. 
 
 Multiple cranial nerve palsy was observed in one patient, who had 
multiple space occupying lesions in the brain on follow up CT brain. 
ACUTE   RETINAL NECROSIS  
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 However the exact nature of the lesions remained unknown as the patient 
expired during follow up. 
 
 One patient presented himself with atypical optic neuritis associated with 
hemiparesis and fever. Thorough systemic evaluation revealed multiple 
space occupying lesions in the brain. Patient’s CD4 count was found to be 
100 cells/ mm. After battery of tests it was diagnosed to be HIV white 
matter disease, progressive in nature.  
          The exact diagnosis was Tumefactive demyelination disease. 
 
 Consecutive optic atrophy was observed in three patients with retinal 
changes. One patient had HIV associated primary optic atrophy. 
 
  
OPTIC NEURITIS AND OPTIC DISC PALLOR 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
SOCIODEMOGRAPHIC STATISTICS 
AGE WISE STATISTICS:          
                                                        Table 32 
AGE 
BISWAS 
ET AL 
GURURAJ ET 
AL 
LAMICHHANE 
G ET AL 
PRESENT 
STUDY 
N 100 100 117 100 
<20 7% 7% NA 5% 
20 -40 74.60% 54% 78.60% 58% 
41-60 
19% 
36% NA 34% 
>60 3% NA 3% 
MEAN 
AGE 
34.16 36.4 30.14+/- 11.82 38.14+/- 11.84 
 
 The mean age of patients in our study was 38.14 +/- 11.84 which fell in 
line with mean age of the comparative studies. 
 
 Majority of the patient prevalence in our study fell under the reproductive 
age group of 20-40 years. This pattern was similarly noticed in Biswas et 
al , Gururaj et al and Lamichhane G et al study. However our prevalence 
rate of 58 % was closely comparable to the Gururaj et al study which had 
54 %. Also comparable with the Gururaj et al study was the decrease in 
prevalence with increase in age. 
 
 Of special mention is the similarity in the prevalence of patients in the age 
group < 20 years. 
 
GENDER STATISTICS: 
Table 33 
GENDER 
BISWAS 
ET AL 
GURURAJ 
ET AL 
LAMICHHANE 
G ET AL 
AMARE 
ET AL 
PRESENT 
STUDY 
N 70 100 117 126 100 
MALE 74% 46% 64.90% 34.12% 59% 
FEMALE 21.42% 54% 35.10% 65.87% 41% 
 
 Our study shows a higher male prevalence in comparison to females. This 
finding was similarly noted in Biswas et al and Lamichhane G et al study. 
 
 As previously mentioned the age gender distribution in our study was not 
significant, p= 0.3. This was also the finding in Lamichhane G et all study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MODE OF TRANSMISSION DISTRIBUTION: 
 
Table 34 
MODE OF 
TRANSMISSION 
BISWAS ET 
AL 
GURURAJ ET 
AL 
PRESENT 
STUDY 
N=70 N=100 N=100 
SEXUAL 60% 81% 91% 
BLOOD 
TRANSFUSION 18.50% 1% 2% 
INJECTIONS 7.10% NA 2% 
 
MTC 7.10% 7% 5% 
   P= 0.1274 
 
 Sexual route was the most common mode of disease transmission, and this 
was observed in study by Biswas et al and Gururaj et al. Gururaj et al had 
1 homosexual route of exposure. 
 
 In our study heterosexual route was the only sexual route of transmission 
and this finding was consistent with the Biswas et al study. 
 
 
 All 5 children in our study acquired infection from vertical transmission. 
 
 Two males from reproductive age acquired infection by sharing of needle. 
 
 P value of 0.1274 signifies that the route of exposure has no impact the 
prevalence of the ocular manifestations. 
 
 
WHO CLINICAL PROFILE: 
Table 35 
WHO CLINICAL 
STAGING 
GURURAJ 
ET AL 
AMARE ET 
AL 
PRESENT 
STUDY 
N 100 126 100 
I 
           62% 
63.50% 73% 
II 13% 7% 
II 
38% 
17.50% 10% 
IV 6.35% 10% 
P           <0.05 <0.01 0.003 
 
 Majority of the patients in our study were observed in clinical stage I and 
II. The findings were similar in the Gururaj et al and Amare et al study. 
 
 It was observed in our study that all patients those who fell under the 
Clinical category III /IV had ocular HIV manifestation, and mostly of the 
opportunistic type. This was equally observed in the studies to which we 
compared to in the above table. 
 
 With p value of 0.003 we can conclude that prevalence of ocular 
manifestation increases with the clinical staging of disease. And this is 
probably due to the increase in the opportunistic infection in these stages. 
This was observed both in  Gururaj et al and the Amare et al study as well. 
 
 
  
CD4 COUNT AND EYE INVOLVEMENT: 
Table 36 
CD4  
COUNTS 
GURURAJ 
ET AL 
PATHAI ET 
AL 
AMARE 
ET AL 
PRESENT 
STUDY 
N 46 26 27 78 
<200 92.90% 76.92% 25.90% 15% 
200-500 
7.10% 23.10% 
48.10% 50% 
>500 25.90% 34% 
P 0.001 <0.01 <0.01 0.0235 
 
 We observed an increased prevalence of ocular manifestations in the CD4 
range of 200 – 500 cells/mm3. This was comparable to the Ethiopian 
study by Amare et al. 
 
 However the prevalence of ocular manifestations in the range < 200 
cells/mm3 fell drastically in comparison Gururaj et al and Pathai et al, and 
significantly with Amare et al. 
 
 P value in our study was 0.0235, which was significant. This significance 
was observed in all the above mentioned studies. 
 
 Hence ocular manifestations is seen to increase significantly with decrease 
in CD4 count, especially in levels < 200 cells/mm3.  
 
 
  
OCULAR MANIFESTATIONS 
ANTERIOR SEGMENT FINDINGS: 
Table 37 
OCULAR FINDINGS 
GURURAJ 
ET AL  
(DAVANGER
E 2013) 
LAMICHHA
NE G ET AL 
(NEPAL 
2010) 
AMARE ET 
AL(NW 
ETHIOPIA 
2011) 
BEKELE 
ET AL 
(ETHIOPA 
2013 ) 
PRESENT 
STUDY 
(2013 ) 
N 100(%) 117(%) 126(%) 348(%) 100(%) 
BLEPHARITIS 1 4(2.5) 3(2.38) 11(3.2) 29 
MOLLUSCUM 
CONTAGIOSUM 
1 0 3(2.38) 9(2.6) 2 
STYE 3 0 0 0 2 
HERPES ZOSTER 42 4(4.27) 3(2.38) 3(0.8) 2 
KAPOSI SARCOMA 
OF ADNEXA  
0 0 1(0.7) 2(0.5) 0 
CONJUNCTIVAL 
SCC/ LYMPHOMA 
0 0 1(0.7) 8(2.3) 0 
SCLERITIS 1 0 0 0 0 
CONJUNCTIVITIS 0 3(1.7) 0 0 6 
CONJUNCTIVAL 
MICROVASCULOPA
THY 
1 0 0 8(2.3) 78 
DRY EYE 3 0 1(0.7) 40(11.5) 0 
KERATITIS(BACTE
RIAL/VIRAL/FUNG
AL) 
34 0 1(0.7) 2(0.5) 2 
ANTERIOR UVEITIS 21 0 5(3.9) 1(0.2) 2 
COMPLICATED 
CATARACT 
NA 0 0 0 2 
INFLAMMATORY 
GLAUCOMA 
NA 0 0 0 1 
 
 Blepharitis and conjunctival microvasculopathy was the commonest 
anterior segment findings observed in this study. The prevalence of both 
of which were significantly higher in comparison to the studies mentioned 
above. 
 
 Kaposi sarcoma and conjunctival squamous cell carcinoma were nil, and 
were comparable to the two Indian studies mentioned above. These 
findings were present in the African studies. And this has been implicated 
due to the homosexual practises. 
 
 Comparing to the two Indian studies, we see differences in most of the 
anterior segment presentations. This can be attributed to the geographical 
change in location of the study. 
 
 
Table 37 
OCULAR FINDINGS (N=100) 
BISWAS ET AL 
(2008) 
PRESENT 
STUDY 
N 100 100 
BLEPHARITIS 1 28 
MOLLUSCUM 2 2 
HERPES ZOSTER OPHTHALMICUS 6 2 
CONJUNCTIVAL 
MICROVASCULOPATHY 
NA 78 
ANTERIOR UVEITIS 4 2 
KAPOSI SARCOMA 1 0 
 
 
 On comparing our study with Biswas et al, we found a similar prevalence 
of blepharitis and conjunctival microvasculopathy. Biswas et al mentions 
in text both the lesion to be the most common anterior segment 
manifestation. The one important patient mentioned above was of non-
healing staphylococcal blepharitis. 
 
 One patient with Kaposi sarcoma was from Dubai. 
 
POSTERIOR SEGMENT: 
Table 38 
OCULAR 
FINDINGS 
BISWAS 
ET AL 
(CHENN
AI 2013) 
GURURAJ 
ET AL 
(DAVANGE
RE 2013) 
LAMICHHA
NE G ET AL 
(NEPAL 
2010 ) 
AMARE ET 
AL 
(NORTHWE
ST 
ETHIOPIA 
2011) 
BEKELE 
ET AL 
(ETHIOP
IA 2013) 
PRESE
NT 
STUDY 
(2013) 
N 1000(%) 100 117(%) 126 348 100 
HIV 
RETINOPATHY 
43(4.3) 12 19(16.23) 9 2(0.6) 4 
CMV RETINITIS 248(24.8) 7 5(4.23) 0 0 2 
TOXOPLASMOSi
S 
28(2.8) 1 2(1.7) 7 1(0.3) 2 
ACUTE 
RETINAL 
NECROSIS 
11(1.1) 1 0 12 0 1 
INTERMEDIATE 
UVEITIS 
18(1.8) 0 0 0 0 1 
OCULAR TB 26(2.6) 4 1(0.9) 0 0 0 
OCULAR 
SYPHILIS 
0 0 0 0 0 0 
OTHER 
RETINAL 
DISEASES 
NA 3 3(2.6) 0 1 2 
CRVO 3(0.3) 0 0 0 0 0 
ENDOPHTHALM
ITIS 
7(0.7) 0 0 0 0 0 
 
 The prevalence of HIV retinopathy, toxoplasmosis acute retinal necrosis 
and uveitis in our study was comparable to the prevalence in Biswas et al 
study. 
The same finding was not so with CMV retinitis. This limitation was 
observed probably due to the sample size in our study.  
 
 Ocular TB and syphilis were not recorded in our study. 
 
  
NEURO-OPHTHAL MANIFESTATIONS: 
Table 39 
OCULAR 
FINDINGS 
BISWAS 
ET AL 
(CHENN
AI 2013) 
GURURAJ 
ET AL 
(DAVANGE
RE 2013) 
LAMICHHA
NE G ET AL  
( NEPAL 
2010) 
AMARE 
ET AL 
(NW 
ETHIOPI
A 2011) 
BEKELE ET 
AL(ETHIOPI
A 2013) 
PRESEN
T 
STUDY 
(2013) 
N 1000 100 117(%) 126(%) 348(%) 100 
CRANIAL 
NERVE 
PALSY 
5(0.5) 4 1 1 5(1.5) 6 
PAPILLEDE
MA 
0 1 2 0 0 0 
OPTIC 
NEURITIS 
0 0 1 0 
4(1.2) 
1 
OPTIC 
ATROPHY 
19 (1.9) 0 0 0 4 
 
 From the above table we observe that cranial nerve palsy was the most 
common neuro ophthalmological manifestation of HIV. Followed by optic 
neuritis and optic atrophy. 
 
ORBIT: 
Table 40 
OCULAR 
FINDING 
BISW
AS ET 
AL 
(2013) 
GURURAJ 
ET AL 
(DAVANG
ERE 2013) 
LAMICHH
ANE G ET 
AL  ( 
NEPAL 
2010) 
AMAR
E ET 
AL 
(NW 
ETHIO
PIA 
2011) 
BEKEL
E ET AL 
(ETHIO
PIA 
2013) 
PRESE
NT 
STUD
Y 
(2013) 
OBITAL 
CELLULI
TIS 
1 1 0 0 0 0 
ORBITA
L 
TUMOR 
0 0 0 0 0 0 
 
 
 We observed no case of orbital cellulitis or any orbital manifestations of 
HIV and this prevalence rate was comparable other studies. 
CONCLUSION 
 HIV infection is a problematic communicable disease present in our 
population, affecting commonly the reproductive age group.   
 
 Disease awareness and prevention programme must be undertaken 
targeting most importantly the unskilled segment of population.  
 
 A proper screening of blood units in the blood banks is a must to prevent 
risk of undue HIV transmission to patients. 
 
 Screening of  antenatal women  with ELISA and taking necessary steps to 
prevent mother to child transmission will minimise the risk of the disease 
in children. 
 
 HIV manifests in the eye  either directly in the form of viral load or causes 
low immunity thereby increasing chances for opportunistic infections. 
 
 With the introduction of HAART, the life expectancy of the patients have 
significantly increased. However the ocular manifestations continue to 
present in innumerable forms. 
 
 Not all patients with early HIV opportunistic infection present to us with 
ocular symptoms until unless the manifestation is severely blinding and 
irreversible. 
 
 Most of the symptomatic patients are the ones with blepharitis and 
conjunctivitis, a non-blinding yet troublesome form of disease 
manifestations. 
 
 The ART centres in India at present practice just the referral of patients 
for ophthalmological examination only when the patient develops ocular 
complaints. 
 
 
 
 With the number of ocular findings observed, our study highlights the 
need for a routine ophthalmological screening of all HIV seropositive 
patients. 
 
 We recommend a routine screening of HIV seropositive patients upon 
diagnosis, prior to starting ART therapy to obtain a baseline ocular status.  
 
 Once the patient is started on HAART , he/she  must  undergo at-least a 
half yearly ocular examination. This is important for two reasons; one to 
look out for immune reconstitution syndromes, two to identify the ocular 
side effects of HAART. 
 
 CD4 counts have to be strictly considered while monitoring these patients. 
It serves both as a risk factor as well as an indicator of opportunistic 
manifestations. 
 
 A very important observation we made was the patients non-consenting to 
any detailed examination outside of the ART centre. This was due to the 
stigma attached to the disease and the fear of being publically recognised 
as HIV seropositive. 
 
 All this indicates a need for provision of ophthalmic setup in the ART 
centre. 
 
 This can be made possible with adequate resources and trained ophthalmic 
personnel.  
 
  
 
 
 
 
 
                       ANNEXURES 
  
ABBREVIATIONS 
 
HIV          HUMAN IMMUNODEFICIENCY VIRUS 
AIDS         ACQUIRED IMMUNODEFECIENCY SYNDROME 
CD          CLUSTER OF DIFFERENTIATION 
RNA         RIBONUCLEIC ACID 
WHO         WORLD HEALTH ORGANISATION 
CDC        CENTRE FOR DISEASE CONTROL 
ART        ANTIRETROVIRAL THERAPY 
HAART        HIGHLY ACTIVE ANTIRETROVIRAL THERAPY 
ELISA        ENZYME LINKED IMMUNOSORBENT ASSAY 
CMV        CYTOMEGALOVIRUS 
ARN       ACUTE RETINAL NECROSIS 
MTC       MOTHER TO CHILD TRANSMISSION 
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PROFORMA 
Name                                        Age                           Sex                          
Occupation                              Marital status             Pre ART/ ART no.                                                    
Mode of transmission             
When diagnosed 
Who clinical stage                           
Duration since diagnosis 
CD4 count baseline                          
CD4 count at present 
Haart initiated                                  
Drug administered 
Associated systemic illness if any  
Ocular complaints /symptoms and its duration: 
 
  
 
 
 
OCULAR EXAMINATION 
Preliminary examination: 
 RE LE 
VISION   
EYELID/LASH   
CONJUNCTIVA   
CORNEA   
ANTERIOR CHAMBER   
IRIS   
PUPIL   
LENS   
IOP   
SCHIRMERS   
 
SLIT LAMP EXAMINATION AND 90D 
RIGHT EYE:                                        LEFT EYE: 
 
DILATED FUNDUS EXAMINATION WITH IDO 
Right eye:                                                         left eye: 
 
DIAGNOSIS: 
TREATMENT: 
  
  
  
RIGHT 
EYE
LEFT 
EYE
ADNEXA ANTERIOR SEGMENT 
1 M
200/201
1
25 M HINDU N COOLIE SEXUAL 2013 28 2013 28
< 12 
MONTHS
3 Y
< 12 
MONTHS
YES NIL PL + PL+
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
2 RB 82/2006 30 F MUSLIM W
HOUSEWI
FE
SEXUAL 2006 870 2013 920
> 60 
MONTHS
4 Y
> 60 
MONTHS
YES NIL      6/6 PL+ - -
3 SB 67/2006 7 F MUSLIM N SCHOOL MTC 2006 140 2013 1007
> 60 
MONTHS
1 Y
> 60 
MONTHS
NO PAST   6/6    6/6
4 U
345/201
1
35 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 56 2013 504
25 - 60 
MONTHS
4 Y
25- 60 
MONTHS
YES NIL PL -    6/6 - -
5 P
907/201
2
4 F HINDU N SCHOOL MTC 2012 2149 2013 2149
13 - 24 
MONTHS
4 N NO NO
CURREN
T
  6/6   6/6
6 M
924/201
2
25 F HINDU Y
HOUSEWI
FE
SEXUAL 2012 336 2013 336
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
NO NIL  6/6  6/6 -
CONJ. 
MICROVASCULOPATH
Y
7 S
935/201
2
29 M HINDU Y CLERK SEXUAL 2012 397 2013 397
13 - 24 
MONTHS
1 N NO NO NIL   6/6   6/6
8 A
677/201
2
32 M HINDU Y
ATTENDE
R
SEXUAL 2012 150 2013 169
13 - 24 
MONTHS
4 Y
13- 24 
MONTHS
YES
CURREN
T
 6/24   6/24
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
9 S
101/201
0
57 F HINDU Y
HOUSEWI
FE
SEXUAL 2010 129 2013 745
25 - 60 
MONTHS
3 Y
25- 60 
MONTHS
YES PAST PL- PL+
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y ,INFLAMMATORY 
GLAUCOMA
10 D
186/200
9
63 M HINDU Y PAINTER SEXUAL 2009 297 2013 496
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/18 6/24 -
CONJ. 
MICROVASCULOPATH
Y
11 S.M
326/201
1
32 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 32 2013 445
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL   6/6    6/6 -
CONJ. 
MICROVASCULOPATH
Y
12 R
702/201
2
46 M HINDU Y DRIVER SEXUAL 2012 320 2013 219
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
YES PAST   6/6   6/6 -
ALLERGIC 
CONJUNCTIVITIS, 
CONJ 
MICROVASCULOPATH
Y
13 N
579/200
9
48 M HINDU Y
DAILY 
WAGER
SEXUAL 2009 280 2013 350
25 - 60 
MONTHS
2 Y
25- 60 
MONTHS
YES PAST 6/6 HM
BLEPHARIT
IS
-
RE
LIG
IO
N OCCUPAT
ION
MODE OF 
TRANSMISS
ION
YEAR OF 
HIV 
DETECTION
SL NO NAME
PRE 
ART/ 
ART NO
AGE SEX
MARITAL 
STATUS
BASELINE 
CD4 
DATE OF 
EXAMIN
ATION
OCULAR FINDINGS
RIGHT EYEPRESEN
T CD4
WHO 
STAGE 
OF 
DISEA
SE
HAAR
T 
REGI
MEN
BEST 
CORRECTED 
VISUAL ACUITY
OCULAR 
SYMPTO
MS
TB 
STATUS
DURATION 
SINCE 
DETECTIO
N
DURATIO
N SINCE 
TREATME
NT
14 U
9621/20
11
28 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 688 2013 650
25 - 60 
MONTHS
1 N NO NO NIL   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
15 PD
566/201
0
34 M HINDU Y COOLIE SEXUAL 2010 361 2013 459
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
16 D
3013/20
13
38 M HINDU Y COOLIE SEXUAL 2013 194 2013 194
< 12 
MONTHS
1 Y
< 12 
MONTHS
NO NIL   6/6   6/6
17 S
417/201
3
26 M HINDU Y
HOTEL 
WORKER
SEXUAL 2009 690 2013 348
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL   6/6   6/6
18 M
335/200
8
41 M HINDU Y COOLIE SEXUAL 2008 72 2013 150
25 - 60 
MONTHS
4 Y
25- 60 
MONTHS
YES PAST
TUNNE
L 
VISION
TUNN
EL 
VISION
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
19 S
1111/20
12
24 M HINDU Y DRIVER SEXUAL 2012 812 2013 467
13 - 24 
MONTHS
1 Y
< 12 
MONTHS
NO NIL   6/6   6/6
20 M
318/201
1
36 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 240 2013 775
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
21 D
1235/20
12
28 F HINDU Y
HOUSEWI
FE
SEXUAL 2012 501 2013 540
13 - 24 
MONTHS
1 N NO NO NIL   6/6   6/6
22 R
370/201
0
45 M HINDU Y
SELF 
EMPLOYE
D
SEXUAL 2010 402 2013 593
25 - 60 
MONTHS
1 N NO NO NIL   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
23 M
229/201
0
55 F HINDU Y
HOUSEWI
FE
SEXUAL 2009 171 2013 148
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/12 6/12 -
CONJ. 
MICROVASCULOPATH
Y
24 V
375/201
1
48 M HINDU Y DRIVER SEXUAL 2010 249 2013 647
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
25 S
443/201
1
46 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 262 2013 646
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
YES NIL   6/6   6/6
BLEPHARIT
IS
ALLERGIC 
CONJUNCTIVITIS
26 P
285/201
0
77 M HINDU W
UNEMPL
OYED
SEXUAL 2010 86 2013 113
25 - 60 
MONTHS
3 Y
25- 60 
MONTHS
NO PAST 6/60 6/60
BLEPHARIT
IS
 -
27 I
675/201
2
45 F HINDU Y COOLIE SEXUAL 2012 265 2013 651
13 - 24 
MONTHS
3 Y
13- 24 
MONTHS
NO PAST   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
28 C
806/201
3
34 M HINDU Y DRIVER SEXUAL 2013 235 2013 300
< 12 
MONTHS
1 Y
< 12 
MONTHS
NO NIL   6/6   6/6
BLEPHARIT
IS
 -
29 A
605/201
2
34 F HINDU Y
DAILY 
WAGER
SEXUAL 2012 193 2013 210
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
YES PAST   6/6   6/6 -
ALLERGIC 
CONJUNCTIVITIS, 
CONJ 
MICROVASCULOPATH
Y
30 E
429/201
1
35 M HINDU Y
LOADMA
N
SEXUAL 2011 349 2013 597
25 - 60 
MONTHS
2 Y
25- 60 
MONTHS
NO NIL   6/6   6/6 -
CONJ. 
MICROVASCULOPATH
Y
31 G
233/201
0
36 F HINDU Y
HOUSEWI
FE
SEXUAL 2010 241 2013 243
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL   6/6   6/6
32 R
898/201
1
20 M HINDU N STUDENT
IV DRUG 
ABUSE
2013 210 2013 210
< 12 
MONTHS
2 Y
< 12 
MONTHS
YES NIL 6/6 6/6
MOLLUSCU
M 
CONTAGIO
SUM
-
33 P
534/201
2
35 M HINDU Y
UNEMPL
OYED
SEXUAL 2010 441 2013 307
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO
CURREN
T
  6/6   6/6
34 G
665/201
2
13 M HINDU N SCHOOL MTC 2012 194 2013 331
13 - 24 
MONTHS
3 Y
13- 24 
MONTHS
NO
CURREN
T
  6/6   6/6
35 E
630/201
2
67 M HINDU Y
UNEMPL
OYED
SEXUAL 2012 431 2013 571
13 - 24 
MONTHS
1 Y
< 12 
MONTHS
NO NIL 6/36 6/36
36 S
732/201
1
57 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 253 2013 312
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
YES NIL 6/12 6/12
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
37 P
282/201
0
32 M HINDU Y
SELF 
EMPLOYE
D
SEXUAL 2009 109 2013 495
25 - 60 
MONTHS
4 Y
25- 60 
MONTHS
YES PAST PL- PL- -
CONJ. 
MICROVASCULOPATH
Y
38 PD
379/201
1
41 M HINDU Y COOLIE SEXUAL 2011 199 2013 591
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL   6/6   6/6
39 M
210/201
0
32 F HINDU Y
HOUSEWI
FE
SEXUAL 2010 120 2013 485
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
40 S
446/201
3
42 M HINDU Y COOLIE SEXUAL 2013 1791 2013 1916
< 12 
MONTHS
1 Y
13- 24 
MONTHS
NO NIL 6/6 6/6
41 R
591/201
2
33 M HINDU Y COOLIE SEXUAL 2012 176 2013 273
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
YES NIL 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
42 V
116/201
0
41 M
CHRISTIA
N
Y
DAILY 
WAGER
SEXUAL 2010 149 2013 454
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
43 N
331/201
1
36 M HINDU Y
DAILY 
WAGER
SEXUAL 2011 120 2013 210
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
44 D
796/201
3
30 F HINDU Y
HOUSEWI
FE
SEXUAL 2013 307 2013 307
< 12 
MONTHS
1 Y
< 12 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
45 G
272/201
2
39 M
CHRISTIA
N
Y WELDER SEXUAL 2012 300 2013 510
13 - 24 
MONTHS
2 Y
13- 24 
MONTHS
YES NIL 6/6 6/6 - -
46 B
290/201
0
46 F HINDU Y
DAILY 
WAGER
SEXUAL 2010 504 2013 532
25 - 60 
MONTHS
1 N NO NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
47 K
283/201
0
36 F HINDU Y
FLOWER 
SELLER
SEXUAL 2010 201 2013 985
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
48 K
485/201
2
40 M HINDU Y DRIVER SEXUAL 2012 142 2013 524
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
49 F
562/201
1
37 M
CHRISTIA
N
Y
DAILY 
WAGER
SEXUAL 2011 210 2013 360
25 - 60 
MONTHS
4 Y
25- 60 
MONTHS
NO NIL 6/60 6/6 - VIRAL KERATITIS
50 T
280/201
0
46 M HINDU Y
ELECTRICI
AN
SEXUAL 2010 218 2013 605
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
51 S
1052/20
11
50 M HINDU Y
SELF 
EMPLOYE
D
SEXUAL 2008 835 2013 526
25 - 60 
MONTHS
1 N NO NO NIL 6/6 6/6
52 M
249/201
0
55 M HINDU Y
DAILY 
WAGER
SEXUAL 2005 962 2013 835
> 60 
MONTHS
1 Y
> 60 
MONTHS
NO NIL 6/12 6/12 -
CONJ. 
MICROVASCULOPATH
Y
53 V
494/201
2
45 F HINDU Y
HOUSEWI
FE
SEXUAL 2012 168 2013 573
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
YES NIL 6/6 6/6
BLEPHARIT
IS
 -
54 M 59/2009 38 M HINDU Y DRIVER SEXUAL 2009 209 2013 562
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6  -
CONJ. 
MICROVASCULOPATH
Y
55 V
253/201
0
32 F HINDU Y
HOUSEWI
FE
SEXUAL 2010 215 2013 375
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/6 6/6
BLEPHARIT
IS
56 G
1472/20
13
38 F HINDU Y
HOUSEWI
FE
BLOOD 
TRANSFUSI
ON
2013 717 2013 780
< 12 
MONTHS
1 N NO NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
57 R
762/201
3
44 M HINDU Y
DAILY 
WAGER
SEXUAL 2013 273 2013 273
< 12 
MONTHS
3 Y
< 12 
MONTHS
NO
CURREN
T
6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
58 G 94/2009 47 F HINDU Y
DAILY 
WAGER
SEXUAL 2009 151 2013 513
25 - 60 
MONTHS
3 Y
25- 60 
MONTHS
NO PAST 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
59 Y
221/201
0
40 M HINDU Y
FISHERM
AN
SEXUAL 2009 127 2013 125
25 - 60 
MONTHS
2 Y
25- 60 
MONTHS
YES
CURREN
T
6/6 6/6
BLEPHARIT
IS
ALLERGIC 
CONJUNCTIVITIS, 
CONJ 
MICROVASCULOPATH
Y
60 B
651/201
2
38 F HINDU Y
SELF 
EMPLOYE
D
SEXUAL 2012 380 2013 314
13 - 24 
MONTHS
1 y
< 12 
MONTHS
NO NIL 6/6 6/6 -
ALLERGIC 
CONJUNCTIVITIS
61 L
1700/20
13
34 M HINDU Y CLERK SEXUAL 2013 360 2013 360
< 12 
MONTHS
1 N NO NO NIL 6/6 6/6 - -
62 V
1555/20
13
43 M HINDU Y
DAILY 
WAGER
SEXUAL 2013 525 2013 525
< 12 
MONTHS
1 N NO NO NIL 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
63 M
186/201
0
35 M HINDU Y
CUSTOM
S
SEXUAL 2010 92 2013 585
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
64 B
303/200
5
31 F HINDU Y
HOUSEWI
FE
SEXUAL 2005 325 2013 570
> 60 
MONTHS
1 Y
> 60 
MONTHS
YES NIL 6/6 6/6 STYE -
65 R
689/201
2
42 M HINDU Y
SELF 
EMPLOYE
D
SEXUAL 2012 217 2013 217
13 - 24 
MONTHS
4 Y
13- 24 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
66 S
647/201
3
44 F HINDU Y
HOUSEWI
FE
SEXUAL 2012 844 2013 1123
13 - 24 
MONTHS
1 Y
< 12 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
67 S
713/201
3
49 M HINDU Y DRIVER SEXUAL 2007 101 2013 803
> 60 
MONTHS
1 Y
> 60 
MONTHS
NO PAST 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
68 M
435/200
4
52 M HINDU Y PAINTER SEXUAL 2004 153 2013 462
> 60 
MONTHS
1 Y
> 60 
MONTHS
NO PAST 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
69 S
705/201
3
40 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 1106 2013 1043
25 - 60 
MONTHS
3 Y
25- 60 
MONTHS
YES NIL 6/36 6/36 -
CONJ. 
MICROVASCULOPATH
Y
70 PK
371/201
1
44 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 63 2013 327
25 - 60 
MONTHS
3 Y
25- 60 
MONTHS
NO PAST 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
71 M
571/201
2
33 F HINDU Y
HOUSEWI
FE
SEXUAL 2008 492 2013 877
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
72 T
708/201
3
52 M HINDU Y
ATTENDE
R
SEXUAL 2007 79 2013 623
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/12 6/12 -
CONJ. 
MICROVASCULOPATH
Y
73 SK
292/201
0
30 M HINDU N
SECURITY 
GUARD
SEXUAL/IV 
DRUG 
ABUSE
2010 198 2013 312
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
YES PAST 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
74 P
405/201
1
55 F HINDU Y
FRUIT 
SELLER
SEXUAL 2011 171 2013 750
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
75 M
598/201
3
32 F HINDU Y COOLIE SEXUAL 2012 114 2013 146
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
NO NIL 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
76 R
1563/20
13
37 M HINDU Y COOLIE SEXUAL 2013 178 2013 178
< 12 
MONTHS
1 Y
< 12 
MONTHS
NO NIL 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
77 L
949/201
1
35 F HINDU Y
DAILY 
WAGER
SEXUAL 2011 759 2013 1045
25 - 60 
MONTHS
1 N NO YES NIL 6/36 6/36
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
78 S
645/201
2
56 M
CHRISTIA
N
Y
DAILY 
WAGER
SEXUAL 2012 153 2013 248
13 - 24 
MONTHS
3 Y
13- 24 
MONTHS
NO PAST 6/6 6/6
79 P 48/2009 36 M HINDU Y
DAILY 
WAGER
BLOOD 
TRANSFUSI
2009 252 2013 542
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
80 VM
759/201
3
42 M HINDU Y COOLIE SEXUAL 2010 169 2013 165
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/60 6/60
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
81 UP
464/201
0
30 M HINDU Y PLUMBER SEXUAL 2010 632 2013 690
25 - 60 
MONTHS
1 N NO NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
82 AM
1184/20
12
7 F HINDU N SCHOOL MTC 2012 711 2013 425
13 - 24 
MONTHS
1 Y
< 12 
MONTHS
YES NIL 6/6 6/6
BLEPHARIT
IS
83 ABR
269/201
0
45 M HINDU Y
MANUAL 
WORK
SEXUAL 2010 249 2013 658
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
84 YD
767/201
3
32 M HINDU Y COOLIE SEXUAL 2013 200 2013 200
< 12 
MONTHS
4 Y
< 12 
MONTHS
YES NIL 6/6 6/6
BLEPHARIT
IS
CONJ. 
MICROVASCULOPATH
Y
85 M
1162/20
13
39 M HINDU Y
SELF 
EMPLOYE
D
SEXUAL 2013 100 2013 100
< 12 
MONTHS
4 Y
< 12 
MONTHS
YES NIL 6/6 PL+ -
CONJ. 
MICROVASCULOPATH
Y
86 M
840/201
3
40 F HINDU Y
FLOWER 
SELLER
SEXUAL 2009 709 2013 355
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
87 P
1173/20
09
55 F HINDU Y
HOUSEWI
FE
SEXUAL 2009 250 2013 400
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/24 6/24 - -
88 S
676/201
0
30 F HINDU Y COOLIE SEXUAL 2010 348 2013 500
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6 - -
89 M
540/201
1
35 M HINDU Y PAINTER SEXUAL 2011 180 2013 457
25 - 60 
MONTHS
2 y
25- 60 
MONTHS
YES PAST 6/6 6/12 - -
90 N
608/201
2
14 M HINDU N STUDENT MTC 2013 318 2013 318
< 12 
MONTHS
2 y
< 12 
MONTHS
YES NIL 6/6 6/6
MOLLUSCU
M 
CONTAGIO
SUM
-
91 S
444/200
8
30 F HINDU Y SWEEPER SEXUAL 2008 350 2013 435
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
YES NIL 6/6 6/6 -
ALLERGIC 
CONJUNCTIVITS
92 E
539/201
1
38 M HINDU Y
DAILY 
WAGER
SEXUAL 2011 335 2013 534
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
93 J
294/201
0
41 M
CHRISTIA
N
Y
SELF 
EMPLOYE
D
SEXUAL 2010 234 2013 398
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO NIL 6/6 6/6
BLEPHARIT
IS
-
94 JM
699/201
2
33 M HINDU Y COOLIE SEXUAL 2012 342 2013 467
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
NO NIL 6/6 6/6
95 LM
709/201
2
60 M HINDU Y
UNEMPL
OYED
SEXUAL 2012 319 2013 410
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
Y
96 P
235/201
1
33 F HINDU Y
HOUSEWI
FE
SEXUAL 2011 270 2013 390
25 - 60 
MONTHS
1 Y
25- 60 
MONTHS
NO PAST 6/6 6/6 -
COMPLICATED 
CATARACT
97 K
1556/20
13
34 M HINDU Y
MANAGE
R
SEXUAL 2013 400 2013 400
< 12 
MONTHS
1 N NO YES NL 6/6 6/6
RECURREN
T STYE
-
98 S
1403/20
12
30 F HINDU Y COOLIE SEXUAL 2012 780 2013 759
13 - 24 
MONTHS
1 N NO YES NIL 6/6 6/6
BLEPHARIT
IS
-
99 D
894/201
2
40 M HINDU Y PLUMBER SEXUAL 2012 338 2013 650
13 - 24 
MONTHS
1 Y
13- 24 
MONTHS
YES NIL 6/6 6/6
100 T
1709/20
13
33 F HINDU Y SWEEPER SEXUAL 2013 560 2013 560
< 12 
MONTHS
1 N NO NO NIL 6/6 6/6 -
CONJ. 
MICROVASCULOPATH
POSTERIOR 
SEGMENT
NEURO 
OPHTHAL
ORBIT ADNEXA
ANTERIOR 
SEGMENT
POSTERIOR 
SEGMENT
NEURO 
OPHTHAL
ORBIT
ACUTE RETINAL 
NECROSIS
- - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
ACUTE 
RETINAL 
NECROSIS
- -
CMV RETINITIS 
BURNT OUT
- - - -
CMV 
RETINITIS 
BURNT OUT
- -
CMV RETINITIS 
BURNT OUT
- - - - - - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
-
MULTIPLE 
CRANIAL 
NERVE 
PALSY
- BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
TOXOPLASMA 
RETINITIS , 
VITRITIS
- - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY , 
INFLAMMATORY 
GLAUCOMA
TOXOPLASM
A RETINITIS , 
VITRITIS
- -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
ALLERGIC 
CONJUNCTIVITIS, 
CONJ 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
NON HEALING 
FUNGAL 
CORNEAL ULCER
- - -
OCULAR FINDINGS
RIGHT EYE LEFT EYE
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
RETINITIS - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
RETINITIS - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
ALLERGIC 
CONJUNCTIVITIS
- - -
- - - BLEPHARITIS  - - - -
- - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS  - - - -
- - - -
ALLERGIC 
CONJUNCTIVITIS, 
CONJ 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - -
MOLLUSCUM 
CONTAGIOSU
M
- - - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
TOXO PLASMA 
RETINITIS
- -  -
CONJ. 
MICROVASCULO
PATHY
TOXO 
PLASMA 
RETINITIS
 -  -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - -
HEALED 
HERPES 
- -  - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - - - - - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS  - - - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS  - - - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
ALLERGIC 
CONJUNCTIVITIS, 
CONJ 
MICROVASCULO
PATHY
- - -
- - -  -
ALLERGIC 
CONJUNCTIVITIS
- - -
HIV 
RETINOPATHY
- - - -
HIV 
RETINOPATH
- -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - - - - - - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
HIV 
RETINOPATH
Y
- -
- - - -
CONJ. 
MICROVASCULO
PATHY, OSSN
- - -
- - - -
CONJ. 
MICROVASCULO
PATHY
- - -
RETINAL 
VASCULITIS
DISC 
PALLOR 
 - -
CONJ. 
MICROVASCULO
PATHY
RETINAL 
VASCULITIS
DISC 
PALLOR 
-
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
INTERMEDIATE 
UVEITIS
- - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
INTERMEDIA
TE UVEITIS
- -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - -  -
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS - - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
- - - BLEPHARITIS
CONJ. 
MICROVASCULO
PATHY
- - -
-
DISC 
PALLOR 
,NASAL 
FIELD 
DEFECT
- - - -
DISC 
PALLOR , 
OPTIC 
NEURITIS
-
HIV 
RETINOPATHY
- - - -
HIV 
RETINOPATH
Y
- -
HIV 
RETINOPATHY
- - - -
HIV 
RETINOPATH
Y
- -
- - -
HERPES 
ZOSTER 
- - - -
- - -
MOLLUSCUM 
CONTAGIOSU
M
- - - -
- - -
ALLERGIC 
CONJUNCTIVITS
- - -
- -  - BLEPHARITIS - - - -
- - -
CONJ. 
MICROVASC
ULOPATHY
- - - -
- - -
COMPLICATE
D CATARACT
- - - -
- -  -
RECURRENT 
STYE
- - - -
- -  - BLEPHARITIS - - - -
- - -
CONJ. 
MICROVASC
- - - -
